Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. Denmark
  4. Nasdaq Copenhagen
  5. H. Lundbeck A/S
  6. News
  7. Summary
    LUN   DK0010287234


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

H Lundbeck A/S : Interpretation Of The Term "export" In The Indian Patent Context

05/31/2021 | 10:10am EDT

A patent titled "Pharmaceutical Composition Comprising Phenyl Piperazine Derivatives as Serotonin Reuptake Inhibitors" (Patent number -IN227963) was granted to H LUNDBECK A/S & ANR on 27 December 2009.  The IIN name of the molecule for which Lundbeck A/S obtained patent is Vortioxetine (anti-depressant drug).

The Plaintiff alleged that the defendants manufactured and exported substantial quantities of generic version of VORTIOXETINE to Latin America and Canada. Further, based on information received from an independent investigation agency appointed by the plaintiff, the defendants had imported the API Vortioxetine thrice in 2016 and were engaged in export of substantial quantities of Vortioxetine Hydrobromide to other countries. It further alleged that Defendant No. 2 (nowhere the name of the second defendant is mentioned) sought environmental clearance at Telangana to expand the manufacturing capacity of Defendant's unit which includes manufacturing various products, one among the list of products being Vortioxetine Hydrobromide.

The defendants argued that the drug was not used in India, and the export of the drug was solely for research and development purpose. However, the defendants failed to provide any evidence which clarifies that the use of the drug was solely for research and development purpose.

Delhi High court decision:

The Delhi High court rejected the arguments presented by the defendants as they failed to provide any evidence in support of their arguments. Further, the court interpreted the term "Export from India" as "Use in India" and granted an interim injunction to the plaintiff.

Excerpts from the order:

Learned counsel for the defendants states that the defendants are not using the product in India but exporting it for the purposes of research and development purposes. However, at the moment, there is no material to come to this conclusion that this substantial amount of exports is only for research and development purposes. Further, under Section 107 of the Patents Act, export of the products from India would amount to use of the product in India.

Considering the averments in the plaint as also the documents filed therewith, this Court finds that the plaintiffs have made out a prima facie case in their favour and in case no ex-parte ad-interim injunction is granted, the plaintiffs would suffer an irreparable loss. The balance of convenience also lies in favour of the plaintiffs and against the defendants. Consequently, an ad-interim injunction is granted in favour of the plaintiffs and against the defendants in terms of prayer (i) and (ii) of para 23 of IA 12589/220 till the next date of hearing before this Court.

We hope this article was a useful read. 

Please feel free check our services page to find out if we can cater to your requirements. You can also contact us  to explore the option of working together. 

Best regards - Team InvnTree   

This work is licensed under a Creative Commons Attribution-Non Commercial 3.0 Unported License

Originally published 19 February2021.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

Ms Poonam Chetry
InvnTree Intellectual Property Services Pvt. Ltd.
#399, 15th Cross, 5th Main
Sector-6, HSR Layout
Bangalore 560102
Tel: 8039467555
Fax: 8039467555
E-mail: Hemanth@invntree.com
URL: www.invntree.com

© Mondaq Ltd, 2021 - Tel. +44 (0)20 8544 8300 - http://www.mondaq.com, source Business Briefing

All news about H. LUNDBECK A/S
09/14HERANTIS PHARMA OYJ : Names Chairman of New Scientific Advisory Board
08/18H LUNDBECK A/S : Drugmaker Lundbeck lowers sales outlook as generic competition ..
08/18H LUNDBECK A/S : Lundbeck continues to deliver solid growth for strategic brands..
08/18H. Lundbeck A/S Reports Earnings Results for the Second Quarter Ended June 30..
08/04H LUNDBECK A/S : Lundbeck enters strategic research collaboration with Rgenta Th..
08/04Rgenta Therapeutics, Inc. Enters into a Collaboration with H. Lundbeck A/S
07/22H LUNDBECK A/S : What do you mean brain health?
07/01Denovo Biopharma LLC Announces In-Licenses Late-Stage Alzheimer's Disease Ass..
06/15#1VOICESUMMIT : Partnering with the advocacy community to further brain health a..
06/11H LUNDBECK A/S : Lundbeck CEO, Deborah Dunsire, warns that we could be on the br..
More news
Analyst Recommendations on H. LUNDBECK A/S
More recommendations
Sales 2021 16 422 M 2 589 M 2 589 M
Net income 2021 1 453 M 229 M 229 M
Net Debt 2021 2 161 M 341 M 341 M
P/E ratio 2021 23,4x
Yield 2021 1,67%
Capitalization 33 818 M 5 337 M 5 331 M
EV / Sales 2021 2,19x
EV / Sales 2022 1,91x
Nbr of Employees 5 603
Free-Float 30,7%
Duration : Period :
H. Lundbeck A/S Technical Analysis Chart | LUN | DK0010287234 | MarketScreener
Technical analysis trends H. LUNDBECK A/S
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 15
Last Close Price 170,20 DKK
Average target price 229,60 DKK
Spread / Average Target 34,9%
EPS Revisions
Managers and Directors
Deborah L. Dunsire President & Chief Executive Officer
Anders G÷tzsche Chief Financial Officer & Executive Vice President
Lars S°ren Rasmussen Chairman
Lars Bang Executive VP-Supply Operations & Engineering
Johan Luthman EVP & Head-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
H. LUNDBECK A/S-18.49%5 337
JOHNSON & JOHNSON4.68%433 701
ROCHE HOLDING AG10.97%321 442
PFIZER, INC.19.23%246 078
NOVO NORDISK A/S50.80%232 556